CIK 0001764013 · Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832771572
- Phone
- 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,030,805
- in 10 filings, $173K under 10b5-1 plans
Net −$1,030,805. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-01 | Venker Eric Chief Executive Officer | Option exercise | +368,750 | $14.46 | $5.3M | 368,750 |
| 2026-04-01 | Venker Eric Chief Executive Officer | Returned to the company | −334,960 | $25.10 | $8.4M | 33,790 |
| 2026-04-01 | Venker Eric Chief Executive Officer | Option exercise · Capped Value Appreciation Rights | −368,750 | 1,106,250 | ||
| 2026-03-18 | Van Tuyl Christopher Chief Legal Officer | Sale | −2,877 | $24.97 | $72K | 147,053 |
| 2026-02-25 | Gloria Melanie Chief Operating Officer | Sale | −1,437 | $26.98 | $39K | 172,074 |
| 2026-02-25 | Gloria Melanie Chief Operating Officer | Sale | −859 | $28.16 | $24K | 171,215 |
| 2026-02-25 | Gloria Melanie Chief Operating Officer | Sale | −942 | $28.90 | $27K | 170,273 |
| 2026-01-21 | Stout Jay S Chief Technology Officer | Sale | −1,977 | $26.03 | $51K | 197,634 |
| 2026-01-07 | Stout Jay S Chief Technology Officer | Sale | −1,148 | $26.51 | $30K | 199,666 |
| 2026-01-07 | Stout Jay S Chief Technology Officer | Sale | −55 | $26.92 | $1K | 199,611 |
| 2025-12-18 | Van Tuyl Christopher Chief Legal Officer | Sale | −8,529 | $26.78 | $228K | 152,214 |
| 2025-12-18 | Van Tuyl Christopher Chief Legal Officer | Sale | −2,284 | $27.38 | $63K | 149,930 |
| 2025-12-12 | Roivant Sciences Ltd. Director | Purchase | +16,666,666 | $21.00 | $350.0M | 113,317,007 |
| 2025-12-01 | Fromkin Andrew J. Director | Sale 10b5-1 | −19,351 | $23.14 | $448K | 88,750 |
| 2025-12-01 | Fromkin Andrew J. Director | Sale 10b5-1 | −2,898 | $23.95 | $69K | 85,852 |
| 2025-12-01 | Hughes Douglas J. Director | Sale 10b5-1 | −13,091 | $23.14 | $303K | 122,682 |
| 2025-12-01 | Hughes Douglas J. Director | Sale 10b5-1 | −1,909 | $23.96 | $46K | 120,773 |
| 2025-11-20 | Gloria Melanie Chief Operating Officer | Sale | −10,251 | $23.54 | $241K | 175,886 |
| 2025-11-20 | Gloria Melanie Chief Operating Officer | Sale | −2,375 | $23.97 | $57K | 173,511 |
| 2025-10-22 | Geffner Michael Chief Medical Officer | Sale | −2,595 | $19.03 | $49K | 217,958 |
Page 6 of 10 · 191 trades